ValiRx plc – LSE:VAL.L

ValiRx stock price today

GBP 36.25
+35.57
+5270.37%
Financial Health
0
1
2
3
4
5
6
7
8
9

ValiRx stock price monthly change

-75.89%
month

ValiRx stock price quarterly change

-75.89%
quarter

ValiRx stock price yearly change

-89.02%
year

ValiRx key metrics

Market Cap
 946.29K
Enterprise value
 74.47M
P/E
 -3.33
EV/Sales
 N/A
EV/EBITDA
 -26.00
Price/Sales
 N/A
Price/Book
 0.25
PEG ratio
 0.64
EPS
 -0.05
Revenue
 N/A
EBITDA
 -4.41M
Income
 -4.40M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

ValiRx stock price history

ValiRx stock forecast

ValiRx financial statements

Profit Margin

ValiRx plc (LSE:VAL.L): Profit margin
Jun 2022 0 -992.48K
Dec 2022 0 -1.37M
Jun 2023 0 -1.03M
Dec 2023 9.6K -1.00M -10440.39%
VAL.L income statement history

Debt to Assets

ValiRx plc (LSE:VAL.L): Debt to assets
Jun 2022 2999973 329.33K 10.98%
Dec 2022 3975946 149.64K 3.76%
Jun 2023 4072350 119.66K 2.94%
Dec 2023 3130438 226.51K 7.24%
VAL.L balance sheet history

Cash Flow

ValiRx plc (LSE:VAL.L): Cash Flow
Jun 2022 -481.99K -2.50K -11.47K
Dec 2022 -1.23M 2.50K 2.26M
Jun 2023 -1.10M -303.30K 1.16M
Dec 2023 -667.89K -2.87K -45.78K
VAL.L cash flow history

ValiRx alternative data

ValiRx
Employees

ValiRx plc (LSE:VAL.L): Employee count
Aug 2023 8
Sep 2023 8
Oct 2023 8
Nov 2023 8
Dec 2023 8
Jan 2024 8
Feb 2024 8
Mar 2024 8
Apr 2024 8
May 2024 8
Jun 2024 8
Jul 2024 16

ValiRx other data

ValiRx
Executives

Insider Compensation
Mr. Kevin J. Alexander (1956) Sec. & Independent Non-Executive Director
 $65,620
Mr. James Gerry Desler FCA (1956) Chief Financial Officer & Executive Director
 $65,040
Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D. (1978) Chief Executive Officer & Director
 $38,380

Frequently Asked Questions (FAQ)

  • What's the price of ValiRx stock today?

    One share of ValiRx stock can currently be purchased for approximately $36.25.

  • When is ValiRx's next earnings date?

    Unfortunately, ValiRx's (VAL.L) next earnings date is currently unknown.

  • Does ValiRx pay dividends?

    No, ValiRx does not pay dividends.

  • How much money does ValiRx make?

    ValiRx has a market capitalization of 946.29K.

  • What is ValiRx's stock symbol?

    ValiRx plc is traded on the LSE under the ticker symbol "VAL.L".

  • What is ValiRx's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of ValiRx?

    Shares of ValiRx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are ValiRx's key executives?

    ValiRx's management team includes the following people:

    • Mr. Kevin J. Alexander Sec. & Independent Non-Executive Director(age: 69, pay: $65,620)
    • Mr. James Gerry Desler FCA Chief Financial Officer & Executive Director(age: 69, pay: $65,040)
    • Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D. Chief Executive Officer & Director(age: 47, pay: $38,380)

  • How many employees does ValiRx have?

    As Jul 2024, ValiRx employs 16 workers, which is 100% more then previous month and 100% more then previous quarter.

  • When ValiRx went public?

    ValiRx plc is publicly traded company for more then 23 years since IPO on 7 Jan 2002.

  • What is ValiRx's official website?

    The official website for ValiRx is valirx.com.

  • How can i contact ValiRx?

    ValiRx can be reached via phone at +44 20 3008 4416.

ValiRx company profile:

ValiRx plc

valirx.com
Exchange:

LSE

Full time employees:

16

Industry:

Biotechnology

Sector:

Healthcare

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.

+44 20 3008 4416
Stonebridge House
Hatfield, CM22 7BD

:
ISIN: GB00BLH13C52
CUSIP: G9313Z140